AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35360551 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) treatment
Number of subjects: 218
Study 35360551 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Control group)
Number of subjects: 218
Study 32781086 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldafermin 1 mg daily for 24 weeks
Number of subjects: 78
Study 32781086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 35109643 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application-based intervention training cognitive and meta-cognitive processes, three times a week for four weeks with remote therapist support
Number of subjects: 20
Study 35109643 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 20
Study 33498768 — intervention group
Group type: EXPERIMENTAL
Intervention: GV oocytes vitrified and IVM (Group GV‐Vit)
Number of subjects: 195
Study 33498768 — intervention group
Group type: EXPERIMENTAL
Intervention: GV oocytes IVM and vitrified at MII stage (Group MII‐Vit)
Number of subjects: 195
Study 33498768 — intervention group
Group type: COMPARATOR
Intervention: GV oocytes IVM (Group not‐Vit)
Number of subjects: 195
Study 32493267 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise program (IG)
Number of subjects: 204
Study 32493267 — intervention group
Group type: COMPARATOR
Intervention: General exercise using elastic bands (CG)
Number of subjects: 204
Study 36041353 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-assisted psychoeducation (n = 30)
Number of subjects: 60
Study 36041353 — intervention group
Group type: COMPARATOR
Intervention: Traditional pen-and-paper brochures (n = 30)
Number of subjects: 60
Study 34649459 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Number of subjects: 5390
Study 34649459 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic Acid (Aspirin)
Number of subjects: 5390
Study 34649459 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (10-year increase)
Number of subjects: 5390
Study 34649459 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 5390
Study 34649459 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 5390
Study 34649459 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (5-U increase)
Number of subjects: 5390
Study 34649459 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP (N-terminal prohormone of brain natriuretic peptide)
Number of subjects: 5390
Study 34649459 — intervention group
Group type: EXPERIMENTAL
Intervention: HAVOC and CHA2DS2-VASc scores
Number of subjects: 5390
Study 35198410 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week therapist-assisted ICBT program with optional 4-week extension of support
Number of subjects: 434
Study 35198410 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week therapist-assisted ICBT program with optional booster lesson
Number of subjects: 434
Study 35198410 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group with both extension and booster
Number of subjects: 434
Study 35198410 — intervention group
Group type: COMPARATOR
Intervention: 8-week therapist-assisted ICBT program
Number of subjects: 434
Study 35198410 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension and booster
Number of subjects: 434
Study 35198410 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ICBT program
Number of subjects: 434
Study 32237205 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynecologic cancer patients pre-radiation therapy
Number of subjects: 157
Study 32237205 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynecologic cancer patients post-radiation therapy
Number of subjects: 157
Study 32237205 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 157
Study 32237205 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynecologic cancer patients (both pre and post RT)
Number of subjects: 157
Study 35289688 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 96
Study 33586087 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy with gustative‐thermic‐tactile stimulation (group A)
Number of subjects: 8
Study 33586087 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined program with neuromuscular electrical stimulation (group B)
Number of subjects: 8
Study 33586087 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 8
Study 32867722 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting lymph node metastasis (LNM) based on tumor diameter, T stage, and tumor differentiation.
Number of subjects: 796
Study 32867722 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting lymph node metastasis (LNM) in the validation set.
Number of subjects: 796
Study 32867722 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram predictions compared to actual observations.
Number of subjects: 796
Study 32867722 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision curve analysis of the LNM nomogram.
Number of subjects: 796
Study 32867722 — intervention group
Group type: EXPERIMENTAL
Intervention: Rates of lymph node metastasis (LNM) in different T stages.
Number of subjects: 796
Study 34530882 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly SMS-questions about pain frequency and pain intensity
Number of subjects: 2892
Study 34530882 — intervention group
Group type: COMPARATOR
Intervention: Control group (followed only by surveys)
Number of subjects: 2892
Study 32700648 — intervention group
Group type: EXPERIMENTAL
Intervention: Young adults (18 to 39 years)
Number of subjects: 1871
Study 32700648 — intervention group
Group type: COMPARATOR
Intervention: Other age groups
Number of subjects: 1871
Study 33428439 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat flexible shoes
Number of subjects: 164
Study 33428439 — intervention group
Group type: COMPARATOR
Intervention: Stable supportive shoes
Number of subjects: 164
Study 33079199 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine with 50% efficacy
Number of subjects: 1971
Study 33079199 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine with 1 year protection duration
Number of subjects: 1971
Study 33079199 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine with 1 in 10,000 major adverse effects
Number of subjects: 1971
Study 33079199 — intervention group
Group type: COMPARATOR
Intervention: FDA emergency use authorization
Number of subjects: 1971
Study 33079199 — intervention group
Group type: COMPARATOR
Intervention: Vaccine from non-US country (China)
Number of subjects: 1971
Study 33079199 — intervention group
Group type: COMPARATOR
Intervention: Vaccine from non-US country (UK)
Number of subjects: 1971
Study 33079199 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorsement from CDC
Number of subjects: 1971
Study 33079199 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorsement from WHO
Number of subjects: 1971
Study 33079199 — intervention group
Group type: COMPARATOR
Intervention: Vaccine from China
Number of subjects: 1971
Study 35776109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian stimulation plus tamoxifen
Number of subjects: 162
Study 35776109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian stimulation plus letrozole
Number of subjects: 162
Study 35776109 — intervention group
Group type: COMPARATOR
Intervention: Standard ovarian stimulation
Number of subjects: 162
Study 33932684 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention group
Number of subjects: 60
Study 33932684 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 60
Study 32019154 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (95 µg/day folate from vegetables)
Number of subjects: 48
Study 32019154 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (191 µg/day folate from vegetables)
Number of subjects: 48
Study 36257214 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 147
Study 36257214 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 147
Study 36257214 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (MBSR + Acupressure)
Number of subjects: 147
Study 36257214 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 147
Study 33749328 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight sessions of web-based time management intervention
Number of subjects: 60
Study 33749328 — intervention group
Group type: COMPARATOR
Intervention: Single-session web-based time management intervention
Number of subjects: 60
Study 34902368 — intervention group
Group type: EXPERIMENTAL
Intervention: RT concurrent with temozolomide (TMZ) (75 mg/m2/d, 7 d/week) followed by adjuvant TMZ (CRT group)
Number of subjects: 37
Study 34902368 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone (RT group, n = 18; 60 Gy in 30 daily fractions)
Number of subjects: 37
Study 34902368 — intervention group
Group type: EXPERIMENTAL
Intervention: RT concurrent with temozolomide (TMZ) (CRT group)
Number of subjects: 37
Study 34902368 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone (RT group)
Number of subjects: 37
Study 34447389 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal protein-specific IgG titres measured at 1, 4, 9, 10, 23, and 24 months of age.
Number of subjects: 101
Study 34447389 — intervention group
Group type: EXPERIMENTAL
Intervention: NTHi protein-specific IgG titres measured at 1, 4, 9, 10, 23, and 24 months of age.
Number of subjects: 101
Study 34447389 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of antibody titres and carriage density for both pathogens.
Number of subjects: 101
Study 35673701 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable pedal machine intervention (60 minutes per working day for 12 weeks)
Number of subjects: 32
Study 33094725 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy (4 L/min)
Number of subjects: 20
Study 33094725 — intervention group
Group type: COMPARATOR
Intervention: Placebo (medical air)
Number of subjects: 20
Study 32781010 — intervention group
Group type: EXPERIMENTAL
Intervention: Real 2 mA tDCS for 20 minutes
Number of subjects: 30
Study 32781010 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 34739863 — intervention group
Group type: EXPERIMENTAL
Intervention: CDED plus partial enteral nutrition
Number of subjects: 44
Study 34739863 — intervention group
Group type: COMPARATOR
Intervention: CDED alone
Number of subjects: 44
Study 34558823 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleic acid polymers (NAPs) + tenofovir disoproxil fumarate (TDF) + pegylated interferon (pegIFN)
Number of subjects: 23
Study 34558823 — intervention group
Group type: COMPARATOR
Intervention: Lead-in TDF monotherapy
Number of subjects: 23
Study 34558823 — intervention group
Group type: EXPERIMENTAL
Intervention: NAPs + pegIFN
Number of subjects: 23
Study 34558823 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after therapy
Number of subjects: 23
Study 34558823 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF monotherapy followed by NAP + pegIFN
Number of subjects: 23
Study 34558823 — intervention group
Group type: EXPERIMENTAL
Intervention: End of therapy
Number of subjects: 23
Study 34558823 — intervention group
Group type: EXPERIMENTAL
Intervention: End of therapy in 5 participants
Number of subjects: 23
Study 36156115 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate vegan diet
Number of subjects: 164
Study 36156115 — intervention group
Group type: COMPARATOR
Intervention: Vegetarian therapeutic diet
Number of subjects: 164
Study 33998271 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor V Leiden (FVL) carriers
Number of subjects: 0
Study 33998271 — intervention group
Group type: COMPARATOR
Intervention: Non-carriers of Factor V Leiden (FVL)
Number of subjects: 0
Study 32331071 — intervention group
Group type: EXPERIMENTAL
Intervention: SEP-363856 (50 or 75 mg/d)
Number of subjects: 245
Study 32331071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 32880252 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality self-training (VRS) program for 2 weeks, consisting of eight sessions.
Number of subjects: 52
Study 32880252 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (WL) group, received no intervention.
Number of subjects: 52
Study 32880252 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality self-training (VRS) program for 2 weeks.
Number of subjects: 52
Study 36105938 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive strength training intervention (CST)
Number of subjects: 123
Study 36105938 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 123
Study 34836278 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum PS128 (PS128) treatment (LT) - 2 capsules (3 × 10^10 CFU/capsule) each morning and evening for 4 weeks
Number of subjects: 8
Study 34836278 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (PT) - 2 capsules for 4 weeks
Number of subjects: 8
Study 34836278 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum PS128 (PS128) treatment (LT)
Number of subjects: 8
Study 34836278 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (PT)
Number of subjects: 8
Study 32280123 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV self-sampling
Number of subjects: 2
Study 32280123 — intervention group
Group type: COMPARATOR
Intervention: Navigation to Pap smear
Number of subjects: 2
Study 32280123 — intervention group
Group type: COMPARATOR
Intervention: Standard cervical cancer screening education
Number of subjects: 2
Study 32280123 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV self-sampling delivered in-person
Number of subjects: 2
Study 32280123 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV self-sampling delivered via mail
Number of subjects: 2
Study 36219046 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapinarof cream 1% QD for 21 days
Number of subjects: 376
Study 36219046 — intervention group
Group type: COMPARATOR
Intervention: Vehicle or other appropriate controls
Number of subjects: 376
Study 32003872 — intervention group
Group type: EXPERIMENTAL
Intervention: Short implants (6 mm)
Number of subjects: 96
Study 32003872 — intervention group
Group type: COMPARATOR
Intervention: Long implants (10 mm)
Number of subjects: 96
Study 32003872 — intervention group
Group type: EXPERIMENTAL
Intervention: Crown-to-implant ratio
Number of subjects: 96
Study 34375789 — intervention group
Group type: EXPERIMENTAL
Intervention: vortioxetine with celecoxib
Number of subjects: 0
Study 34375789 — intervention group
Group type: COMPARATOR
Intervention: vortioxetine with placebo
Number of subjects: 0
Study 34265015 — intervention group
Group type: EXPERIMENTAL
Intervention: POCUS‐SPA
Number of subjects: 114
Study 34265015 — intervention group
Group type: EXPERIMENTAL
Intervention: BC
Number of subjects: 114
Study 34265015 — intervention group
Group type: COMPARATOR
Intervention: SPA
Number of subjects: 114
Study 33408691 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligopin
Number of subjects: 80
Study 33408691 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 80
Study 33296620 — intervention group
Group type: EXPERIMENTAL
Intervention: nGVS
Number of subjects: 36
Study 33296620 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 36
Study 34262113 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma treatment
Number of subjects: 22
Study 34262113 — intervention group
Group type: COMPARATOR
Intervention: Sham control treatment
Number of subjects: 22
Study 35596633 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso-calorie diet + Food for Special Dietary Use (FSDU) (2 portions per day for 14 days)
Number of subjects: 20
Study 35596633 — intervention group
Group type: COMPARATOR
Intervention: Iso-calorie diet (ICD) alone
Number of subjects: 20
Study 35596633 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso-calorie diet + FSDU
Number of subjects: 20
Study 33298342 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment regimens modified to reduce toxicity in older/senior patients; specific dosage and duration not mentioned.
Number of subjects: 0
Study 33298342 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessments to select older patients for rigorous treatment regimens; specific assessment methods not mentioned.
Number of subjects: 0
Study 33298342 — intervention group
Group type: EXPERIMENTAL
Intervention: Broadened clinical trial inclusion criteria for older/senior patients; specific criteria not mentioned.
Number of subjects: 0
Study 34302956 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperacute neuropathic pain assessment using DN4 within the first 5 days post-injury
Number of subjects: 78
Study 34302956 — intervention group
Group type: EXPERIMENTAL
Intervention: Late presenting neuropathic pain
Number of subjects: 78
Study 33780665 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 668
Study 33780665 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 668
Study 35578722 — intervention group
Group type: EXPERIMENTAL
Intervention: Family participatory nursing model based on WeChat platform
Number of subjects: 100
Study 33711216 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) levels in T2DM cases
Number of subjects: 60
Study 33711216 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-2 (IL-2) levels in non-diabetic controls
Number of subjects: 60
Study 33711216 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-18 (IL-18) levels in T2DM cases
Number of subjects: 60
Study 33711216 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-18 (IL-18) levels in non-diabetic controls
Number of subjects: 60
Study 32559735 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month self- and family management support programs
Number of subjects: 56
Study 32559735 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study 36295645 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal massage by a specialized physiotherapist
Number of subjects: 81
Study 36295645 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-applied perineal massage
Number of subjects: 81
Study 36295645 — intervention group
Group type: COMPARATOR
Intervention: Ordinary obstetric care (Control)
Number of subjects: 81
Study 32701199 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily (3 weeks on, 1 week off)
Number of subjects: 48
Study 32701199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 32701199 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 48
Study 35935309 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX 1.0 ug/kg
Number of subjects: 97
Study 35935309 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX 0.8 ug/kg
Number of subjects: 97
Study 35935309 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX 0.5 ug/kg
Number of subjects: 97
Study 35935309 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl solution 10 mL (Control)
Number of subjects: 97
Study 34180425 — intervention group
Group type: EXPERIMENTAL
Intervention: SSC exercise program plus physical rehabilitation
Number of subjects: 42
Study 34180425 — intervention group
Group type: COMPARATOR
Intervention: Standard physical rehabilitation
Number of subjects: 42
Study 32991582 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Tape (DT)
Number of subjects: 45
Study 32991582 — intervention group
Group type: COMPARATOR
Intervention: Kinesio Tape (KT)
Number of subjects: 45
Study 32991582 — intervention group
Group type: COMPARATOR
Intervention: No tape (Control)
Number of subjects: 45
Study 36086735 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-customized exercises including dynamic thoracic mobility, trunk stabilization exercises, and static stretching during warm-up.
Number of subjects: 70
Study 36086735 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 70
Study 33909358 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation robot rehabilitation training synchronizing acupuncture exercise therapy
Number of subjects: 50
Study 33909358 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture exercise therapy (Control)
Number of subjects: 50
Study 36007871 — intervention group
Group type: EXPERIMENTAL
Intervention: Late evening snack and oral amino acid capsules (LES and OAA)
Number of subjects: 91
Study 36007871 — intervention group
Group type: EXPERIMENTAL
Intervention: Late evening snack (LES)
Number of subjects: 91
Study 36007871 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study 34018290 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mmol/kg gadobenate
Number of subjects: 352
Study 34018290 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mmol/kg gadobenate
Number of subjects: 352
Study 33068346 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture of 'Zhibian (BL 54) through Shuidao (ST 28)'
Number of subjects: 90
Study 33068346 — intervention group
Group type: COMPARATOR
Intervention: Non‐permeable sham acupuncture at Zhibian (BL 54)
Number of subjects: 90
Study 34042156 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 74
Study 34042156 — intervention group
Group type: COMPARATOR
Intervention: Anti-TNF
Number of subjects: 74
Study 32011196 — intervention group
Group type: EXPERIMENTAL
Intervention: A-PRP injections
Number of subjects: 90
Study 32011196 — intervention group
Group type: COMPARATOR
Intervention: AA-PRP injections
Number of subjects: 90
Study 34882161 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy dietary pattern (HDP) only
Number of subjects: 24
Study 34882161 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy dietary pattern (HDP) with 15 g day-1 wolfberries
Number of subjects: 24
Study 34882161 — intervention group
Group type: COMPARATOR
Intervention: Control (HDP only)
Number of subjects: 24
Study 32947492 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cycle of canalith repositioning procedure (CRP)
Number of subjects: 143
Study 32947492 — intervention group
Group type: COMPARATOR
Intervention: Multiple cycles of canalith repositioning procedure (CRP)
Number of subjects: 143